Quick summary
Carfilzomib (Kyprolis) is an FDA-approved second-generation proteasome inhibitor for relapsed/refractory multiple myeloma. Unlike bortezomib, it binds irreversibly and has greater selectivity, resulting in less peripheral neuropathy but requiring cardiac monitoring.
Overview
Carfilzomib (Kyprolis) is an FDA-approved second-generation tetrapeptide epoxyketone proteasome inhibitor used for the treatment of relapsed or refractory multiple myeloma. Unlike bortezomib, it binds the proteasome irreversibly, conferring greater selectivity and potency. It is approved as monotherapy and in combination with lenalidomide plus dexamethasone or daratumumab plus dexamethasone.
Mechanism of action
Carfilzomib is a tetrapeptide epoxyketone that covalently and irreversibly inhibits the chymotrypsin-like (CT-L) proteolytic activity of the 20S proteasome catalytic core. The alpha,beta-epoxyketone pharmacophore forms a morpholine adduct with the N-terminal threonine of the beta5 subunit, permanently inactivating the active site. Proteasome inhibition leads to accumulation of poly-ubiquitinated proteins, triggering endoplasmic reticulum stress, activation of the unfolded protein response, upregulation of pro-apoptotic proteins such as NOXA and BIM, and suppression of NF-κB-mediated pro-survival signaling. Because it binds irreversibly, carfilzomib's pharmacodynamic effect outlasts its short plasma half-life. Compared to bortezomib, it has minimal off-target activity against serine proteases, which reduces peripheral neuropathy.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| relapsed/refractory multiple myeloma (monotherapy) | intravenous | 20–27 mg/m² | Days 1, 2, 8, 9, 15, 16 of 28-day cycle | Cycle 1: 20 mg/m² IV over 10 min on Days 1–2; if tolerated, escalate to 27 mg/m² for subsequent doses. Pre-hydrate and post-hydrate during Cycles 1–2. Monitor BP and cardiac function. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Carfilzomib received accelerated FDA approval in 2012 for patients with relapsed/refractory multiple myeloma after at least two prior therapies. The ASPIRE trial (carfilzomib + lenalidomide + dexamethasone vs. lenalidomide + dexamethasone) showed a 26.3-month median PFS vs. 17.6 months (HR 0.69). The ENDEAVOR trial demonstrated superiority over bortezomib-dexamethasone. Cardiovascular toxicity, particularly hypertension and cardiac failure, is the primary dose-limiting concern and requires monitoring.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Carfilzomib for synergistic effects.
Legal status
FDA-approved since 2012 for relapsed/refractory multiple myeloma. Administered intravenously in an oncology setting with required cardiac and renal monitoring. Not a controlled substance. Subject to REMS program for select combination regimens.
Sourcing & access
Prescription required
Carfilzomib is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Carfilzomib (Kyprolis) is a tetrapeptide epoxyketone proteasome inhibitor approved for relapsed or refractory multiple myeloma. It is a second-generation agent that irreversibly inhibits the proteasome, providing greater potency and selectivity than first-generation bortezomib.
Carfilzomib irreversibly binds the proteasome (vs. bortezomib's reversible binding) and has minimal off-target activity against serine proteases, significantly reducing peripheral neuropathy. However, it carries greater cardiovascular toxicity risk requiring cardiac monitoring.
The ASPIRE trial showed carfilzomib plus lenalidomide and dexamethasone achieved a median progression-free survival of 26.3 months versus 17.6 months for lenalidomide and dexamethasone alone. The ENDEAVOR trial demonstrated superiority over bortezomib-dexamethasone.
Cardiovascular toxicity is the primary concern, including hypertension and cardiac failure. Other side effects include dyspnea, anemia, thrombocytopenia, fatigue, and pyrexia. Blood pressure and cardiac function must be monitored during treatment.
Research references
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyPubMed
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibPubMed
- The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myelomaPubMed
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaPubMed
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialPubMed